Title:
A Phase III Clinical Trial for Test Use and Document Creation Only
Indication:
Miscellaneous
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph 3 BYL719 + nabpax TNBC PIK3CA
View
Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph 3 BYL719 + nabpax TNBC PIK3CA
View
Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph 3 BYL719 + nabpax TNBC PIK3CA
View
Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph 3 BYL719 + nabpax TNBC PIK3CA
View
Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06)
View
Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06)
View
Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- BC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- BC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- BC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- BC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 adv CC
View
Description: A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC
View
Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC
View
Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC
View
Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC
View
Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 Pac-Carbo-Oreg EO FT or PC
View
Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 Nira Pembro Stg 3/4 NSCLC
View
Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
PH3 Nira Pembro Stg 3/4 NSCLC
View
Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
PH3 Nira Pembro Stg 3/4 NSCLC
View
Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
PH3 Nira Pembro Stg 3/4 NSCLC
View
Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
View
Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
View
Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
View
Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
View
Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 Bren Vedo Lena Ritux r/r BC Lymph
View
Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)
Indication:
Lymphomas
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
PH3 Bren Vedo Lena Ritux r/r BC Lymph
View
Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
PH3 Bren Vedo Lena Ritux r/r BC Lymph
View
Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
PH3 Bren Vedo Lena Ritux r/r BC Lymph
View
Description: A randomized double-blind placebo-controlled active-comparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)(SGN35-031)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Vene Aza HR-MDS
View
Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Navi Ruxo Myelofibrosis
View
Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Indication:
Myelofibrosis
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Navi Ruxo Myelofibrosis
View
Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Indication:
Myelofibrosis
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Navi Ruxo Myelofibrosis
View
Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Indication:
Myelofibrosis
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Navi Ruxo Myelofibrosis
View
Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Indication:
Myelofibrosis
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 Alpe BYL719 Olap BRCA OC
View
Description: EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 Pac-Carbo-Oreg EO FT or PC
View
Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC
View
Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
PH3 Pac-Carbo-Oreg EO FT or PC
View
Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III